Compare Abeona Therapeutics Inc (ABEO) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Li Auto Inc — how do they compare? Abeona Therapeutics Inc trades at $7.44 (market cap $424.33M), while Li Auto Inc trades at $12.67 (market cap $12.54B). The key difference: Li Auto Inc is far larger — about 29.6× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | LI | |
|---|---|---|
Market Cap | $424.33M | $12.54B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $26.69 |
52-Week Low | $4.17 | $11.74 |
Enterprise Value | $279.23M | $1.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
Li Auto (LI) trades at $12.95, up 2.05% today, amid mixed technical signals with a bearish overall trend. The company reported declining revenue from $144.5B in 2024 to $112.3B in 2025, with net income dropping to $1.12B. Recent vehicle deliveries show modest growth, with 30,468 vehicles delivered in July 2026. Analyst consensus remains divided with a $14.80 price target, suggesting potential upside from current levels despite near-term challenges.
The outlook for LI is cautious with revenue contraction and profitability pressures, though the EV market in China offers long-term growth potential. Key risks include intense domestic competition and execution challenges with new vehicle launches. Investment opportunity exists if the company can stabilize margins and regain growth momentum, supported by analyst optimism for recovery from 2027 onwards.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
